17 de octubre de 2019
  • Miércoles, 16 de Octubre
  • 31 de agosto de 2009

    Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets (y 2)

    Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

    Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

    * In the SPIRIT II trial, both TAXUS Express2 (73 percent of lesions) and TAXUS Liberte (27 percent of lesions) were used as controls.

    ** In the SPIRIT III trial, TAXUS Express2 was used as the control.

    *** Event rates are based on Kaplan-Meier estimates. P-values are for descriptive purposes only.

    EDITOR'S NOTE: Additional background information, including fact sheets and images, are available to members of the international media through the XIENCE PRIME media kit at www.xienceprimemediakit.com

    Media, Jonathon Hamilton, +1-408-845-3491, or Jennie Kim, +1-408-845-1755, or Financial, John Thomas, +1-847-938-2655, or Tina Ventura, +1-847-935-9390, all of Abbott